5 minOn July 7, 2026, Compass Pathways announced the 26-week (6-month) follow-up results from COMP006, its second pivotal Phase 3 trial evaluating COMP360 (a synthetic formulation of psilocybin) for treatment-resistant depression (TRD). The data confirm that COMP360 maintains its previously reported rapid onset of effect while further validating the durability and reproducibility of its therapeutic benefit.
With the successful completion of both the COMP006 and COMP005 pivotal trials, COMP360 has become the first classic psychedelic to consistently demonstrate a rapid onset, significant durability, and reproducibility of effect across two large-scale, randomized, controlled Phase 3 clinical studies for TRD.
Clinical Breakthrough: Proving Efficacy in a Highly Challenging Patient Population
The participants in the COMP006 trial represent one of the most difficult-to-treat cohorts in psychiatry. On average, these patients had been suffering from their current depressive episode for over three years and had a history of more than six lifetime depressive episodes. Despite this high degree of chronicity, COMP360 demonstrated robust clinical benefits:
-
Core Efficacy Data: Among participants treated with two 25 mg doses of COMP360, 39% achieved a clinically meaningful reduction in MADRS (Montgomery-Åsberg Depression Rating Scale) scores (≥ 25%) by week 6, with this benefit maintained through at least week 26.
-
Reproducibility: These results are highly consistent with the previously reported COMP005 trial data. Furthermore, the administration of a second dose was shown to further strengthen the clinical benefit.
-
Remission Rates: Of those who achieved a clinical response at week 6, nearly 30% went on to achieve full clinical remission during the subsequent treatment interval.
Dr. Guy Goodwin, Chief Medical Officer of Compass Pathways, emphasized that achieving consistent, rapid, and durable clinical effects across two large, rigorously designed Phase 3 studies in such a highly chronic and treatment-resistant population is a rare and remarkable achievement in psychiatry.
A Unique Therapeutic Model: From "Daily Pills" to "On-Demand" Treatment
The emergence of COMP360 signals a profound shift in the mental health treatment paradigm. While traditional antidepressants require daily or frequent dosing—often accompanied by side effects and concerns over dependency—COMP360 offers a different clinical logic:
-
Rapid Onset: Improvements were observed almost immediately following administration, with effects showing high reproducibility across multicenter trials.
-
Durable Relief: Data support a durable therapeutic effect lasting at least 6 months, suggesting that patients may only require a few treatments per year to maintain stability.
-
Safety Profile: Throughout the 26-week follow-up, COMP360 demonstrated a favorable safety and tolerability profile. The vast majority of treatment-emergent adverse events (TEAEs) were transient, primarily occurring on the day of dosing, with no new safety signals identified.
Accelerating Toward Regulatory Approval: Commercial Launch Expected in 2027
Following the positive conclusion of the COMP006 trial, Compass Pathways is accelerating its regulatory roadmap:
-
NDA Submission: The company is currently engaged in the rolling New Drug Application (NDA) submission and initial review process with the U.S. FDA, with the final submission on track for completion in Q4 2026.
-
Commercial Readiness: Compass is actively preparing for launch, anticipating a commercial rollout in the first half of 2027, pending FDA approval and DEA rescheduling.
-
Pipeline Expansion: Beyond TRD, Compass is advancing late-stage clinical programs for post-traumatic stress disorder (PTSD), aiming to provide effective new options for millions of patients currently underserved by existing therapies.
Expert Perspective: A Paradigm Shift in Psychiatry
Dr. Tobias Marton, Chief Medical Officer at Mindful Health Solutions, noted that these results are a significant source of optimism for the field. In his clinical practice, he works with many patients struggling with severe, chronic depression who have failed to respond to standard antidepressants. For these patients, COMP360 represents more than just a drug; it is an innovative tool capable of significantly reducing suffering and improving quality of life.
The success of COMP360 signals that the mental health field is moving beyond the "management of residual symptoms" toward the pursuit of higher-level disease remission. As Compass Pathways moves toward the final NDA submission later this year, this innovative psilocybin therapy is well-positioned to establish a new standard of care, potentially changing the trajectory for millions of patients living with treatment-resistant depression worldwide.
